tiprankstipranks
Trending News
More News >
Avingtrans PLC (GB:AVG)
LSE:AVG

Avingtrans (AVG) AI Stock Analysis

Compare
12 Followers

Top Page

GB:AVG

Avingtrans

(LSE:AVG)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 5.2)
Rating:70Outperform
Price Target:
597.00p
▲(24.38% Upside)
Avingtrans' overall stock score is driven by strong financial performance and positive corporate events, which enhance its growth prospects. While the technical analysis suggests a neutral trend, the valuation indicates potential overvaluation. The absence of earnings call data limits insights into management's outlook.
Positive Factors
Balance sheet health
A low debt-to-equity ratio (0.23) and stable capital structure provide durable financial flexibility. This lets Avingtrans fund project delivery, invest in tooling or acquisitions, and withstand multi-month project timing mismatches without needing urgent external financing.
Revenue growth trends
Sustained top-line growth reflects diversified project wins and repeat aftermarket work across nuclear and advanced engineering. Durable revenue expansion improves scale, supports long-term investment in capabilities, and reduces reliance on any single contract for company-wide growth.
Free cash flow improvement
A large increase in free cash flow and strong FCF-to-net-income conversion enhance self-funding capacity. Over the medium term this strengthens the firm's ability to finance capex, support through-life service offerings, and reduce reliance on external capital for growth or working capital.
Negative Factors
Low net profitability
A 4.19% net margin remains modest for engineered-product and services businesses. Low absolute margins limit the buffer for cost shocks or contract overruns, constrain reinvestment capacity, and make long-term profitability sensitive to competitive pricing and input-cost inflation.
Weak operating cash conversion
An OCF-to-net-income ratio of 0.21 implies earnings are not yet fully converted to operating cash, likely due to milestone timing or working capital in project contracts. Persistently weak conversion raises the risk of short-term cash strain and limits agility to fund growth without using FCF or debt.
End-market concentration and cyclicality
Heavy exposure to nuclear and aerospace ties performance to cyclical public programs and industrial cycles. Revenue and project pipelines can swing with government funding or aerospace OEM demand, increasing structural volatility in order timing and making long-term forecasting and capacity planning harder.

Avingtrans (AVG) vs. iShares MSCI United Kingdom ETF (EWC)

Avingtrans Business Overview & Revenue Model

Company DescriptionAvingtrans plc manufactures and sells engineered components, systems, and services to the energy, medical, and infrastructure industries worldwide. It operates in three segments: Energy-EPM, Energy-PSRE, and Medical-MII. The company designs, manufactures, integrates, and services electric motors and pumps, steam turbines, gas compressors, pressure vessels, blast doors, containers, and skidded systems. It also designs and manufactures equipment for the medical, science and research communities, including products for medical diagnostic equipment; high performance pressure, vacuum vessels, and composite materials for research organizations; and superconducting magnets and helium-free cryogenic systems for use in magnetic resonance imaging and nuclear magnetic resonance. The company was incorporated in 1985 and is based in Chatteris, the United Kingdom.
How the Company Makes MoneyAvingtrans generates revenue through multiple streams, primarily by providing component manufacturing and engineering solutions to major customers in the aerospace, defense, and energy sectors. The company earns money by selling high-precision parts and systems, often through long-term contracts with key industry players. Significant partnerships with OEMs (original equipment manufacturers) and other industry leaders enhance its market position and stability of revenue. Additionally, Avingtrans may also benefit from government contracts in the defense sector, which can provide substantial financial support and contribute to its overall earnings.

Avingtrans Financial Statement Overview

Summary
Avingtrans exhibits robust financial performance with consistent revenue growth and improving profitability margins. The balance sheet is strong, characterized by low leverage and effective equity utilization. Cash flow metrics show significant improvement, enhancing the company's financial flexibility. Overall, Avingtrans is well-positioned for future growth, though maintaining margin improvements and cash flow stability will be crucial.
Income Statement
75
Positive
Avingtrans has shown consistent revenue growth over the years, with a notable increase of 3.96% in the latest period. The gross profit margin is healthy at 30.28%, although it has slightly decreased from previous years. The net profit margin has improved to 4.19%, indicating better profitability. EBIT and EBITDA margins have also shown positive trends, reflecting efficient operations.
Balance Sheet
70
Positive
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.23, suggesting prudent financial management. Return on equity has improved to 5.80%, indicating effective use of equity to generate profits. The equity ratio remains stable, showing a solid capital structure.
Cash Flow
65
Positive
Avingtrans has demonstrated significant improvement in free cash flow, with a growth rate of 61.75%. The operating cash flow to net income ratio is 0.21, indicating moderate cash generation relative to net income. The free cash flow to net income ratio of 0.76 reflects a strong cash conversion cycle.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue156.41M156.41M136.62M116.44M99.08M98.52M
Gross Profit48.43M47.36M44.04M36.86M32.59M28.38M
EBITDA15.70M15.75M12.54M13.20M12.02M11.03M
Net Income6.56M6.56M3.66M5.19M6.48M3.99M
Balance Sheet
Total Assets192.76M192.76M186.34M155.41M154.69M142.61M
Cash, Cash Equivalents and Short-Term Investments8.56M8.56M12.12M17.72M24.29M30.08M
Total Debt25.47M25.47M23.96M8.58M10.96M9.80M
Total Liabilities77.53M77.53M73.33M46.96M48.88M43.65M
Stockholders Equity113.14M113.14M110.44M106.04M103.82M97.30M
Cash Flow
Free Cash Flow8.74M8.80M-11.06M985.00K-1.10M4.03M
Operating Cash Flow11.56M11.61M1.33M9.68M3.88M6.45M
Investing Cash Flow-14.29M-14.29M-13.58M-12.52M-9.35M24.56M
Financing Cash Flow-436.00K-436.00K6.78M-3.40M-371.00K-5.85M

Avingtrans Technical Analysis

Technical Analysis Sentiment
Positive
Last Price480.00
Price Trends
50DMA
495.79
Positive
100DMA
484.71
Positive
200DMA
439.82
Positive
Market Momentum
MACD
14.34
Negative
RSI
80.06
Negative
STOCH
90.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVG, the sentiment is Positive. The current price of 480 is below the 20-day moving average (MA) of 499.75, below the 50-day MA of 495.79, and above the 200-day MA of 439.82, indicating a bullish trend. The MACD of 14.34 indicates Negative momentum. The RSI at 80.06 is Negative, neither overbought nor oversold. The STOCH value of 90.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AVG.

Avingtrans Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
£179.73M27.375.87%1.02%14.49%76.33%
69
Neutral
£1.32B48.274.10%3.30%-6.95%-52.08%
67
Neutral
£653.37M23.898.04%4.87%-7.30%-59.71%
65
Neutral
£116.08M24.053.82%6.69%-13.30%-60.03%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
61
Neutral
£101.50M-8.12-17.46%21.17%-237.25%
46
Neutral
£414.26M-9.10-18.47%57.73%-67.12%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:AVG
Avingtrans
542.50
166.56
44.30%
GB:BOY
Bodycote
766.50
142.42
22.82%
GB:CGS
Castings
267.00
20.45
8.29%
GB:ITM
ITM Power
67.10
31.18
86.80%
GB:MPAC
Mpac Group PLC
337.50
-241.50
-41.71%
GB:MGAM
Morgan Advanced Materials
236.50
-6.84
-2.81%

Avingtrans Corporate Events

Business Operations and Strategy
Avingtrans Grants Share Options Tied to Inflation-Linked EPS Growth
Positive
Jan 12, 2026

Avingtrans plc has granted options over 293,000 ordinary shares to non-PDMR employees under its Share Option Plan, with an exercise price of 515.0 pence per share, as part of its long-term incentive arrangements. The options will vest after three years and are contingent on the company’s adjusted earnings per share at least matching the increase in the Retail Prices Index over the vesting period, aligning employee rewards with both company performance and inflation-protected shareholder value.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Avingtrans Names Stuart Gall to Lead Medical and Industrial Imaging Division
Positive
Jan 12, 2026

Avingtrans has appointed experienced MedTech executive Stuart Gall as Chief Executive Officer of its medical and industrial imaging division, effective 1 January 2026, tasking him with driving the strategic development and commercialisation of portfolio businesses Adaptix, Magnetica and Scientific Magnets. Gall’s track record in scaling medical technology companies from university spin-outs to globally partnered, publicly listed businesses is expected to accelerate market adoption of Avingtrans’ disruptive imaging technologies and support the Group’s efforts to enhance the value of this division for shareholders and strengthen its positioning in high-growth medical and industrial imaging markets.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Avingtrans Announces New COO and Strong AGM Results
Positive
Nov 27, 2025

Avingtrans plc announced the successful passage of all resolutions at its Annual General Meeting, including the appointment of Austen Adams as Group Chief Operating Officer. This appointment aligns with the company’s strong performance and market expectations, potentially enhancing its operational capabilities and industry positioning.

The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Avingtrans PLC Executives Exercise Share Options
Neutral
Nov 14, 2025

Avingtrans PLC announced the exercise of 591,614 options over ordinary shares by CEO Steve McQuillan and CFO Stephen King as part of the Company’s Executive Shared Ownership Plans. This transaction will not result in the issuance of new shares, maintaining the total number of shares with voting rights at 33,130,422. The exercise of these options reflects the company’s internal management strategies and may have implications for shareholder calculations under the Financial Conduct Authority’s rules.

The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Avingtrans’ Adaptix Secures FDA Clearance for 3D Orthopaedic Imaging System
Positive
Nov 10, 2025

Avingtrans plc announced that its subsidiary, Adaptix Limited, has received FDA 510(k) clearance for its Adaptix Ortho350, a 3D imaging system for orthopaedic use. This clearance allows Adaptix to enter the U.S. healthcare market, marking a significant milestone in its mission to transform radiology. The Ortho350 offers low-dose, high-quality imaging at the point-of-care, enhancing diagnostic accuracy and patient outcomes. This achievement is expected to open new opportunities in the substantial U.S. orthopaedic imaging market, validating the commercial potential of Adaptix’s technology.

The most recent analyst rating on (GB:AVG) stock is a Hold with a £538.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025